JP2002528123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528123A5 JP2002528123A5 JP2000579757A JP2000579757A JP2002528123A5 JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5 JP 2000579757 A JP2000579757 A JP 2000579757A JP 2000579757 A JP2000579757 A JP 2000579757A JP 2002528123 A5 JP2002528123 A5 JP 2002528123A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- antigen
- sequence
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 description 53
- 108091028043 Nucleic acid sequence Proteins 0.000 description 40
- 239000003814 drug Substances 0.000 description 27
- 239000000427 antigen Substances 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 229940079593 drug Drugs 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000001461 cytolytic effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 244000053095 fungal pathogen Species 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 244000052613 viral pathogen Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10716998P | 1998-11-05 | 1998-11-05 | |
| US60/107,169 | 1998-11-05 | ||
| PCT/US1999/026291 WO2000026385A1 (en) | 1998-11-05 | 1999-11-05 | Nucleic acid constructs for genetic immunization |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002528123A JP2002528123A (ja) | 2002-09-03 |
| JP2002528123A5 true JP2002528123A5 (https=) | 2006-12-21 |
Family
ID=22315199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000579757A Pending JP2002528123A (ja) | 1998-11-05 | 1999-11-05 | 遺伝子免疫のための核酸構築物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1119630B1 (https=) |
| JP (1) | JP2002528123A (https=) |
| AT (1) | ATE315658T1 (https=) |
| AU (1) | AU775939B2 (https=) |
| CA (1) | CA2349505A1 (https=) |
| CY (1) | CY1105600T1 (https=) |
| DE (1) | DE69929470T2 (https=) |
| DK (1) | DK1119630T3 (https=) |
| ES (1) | ES2257879T3 (https=) |
| IL (1) | IL142980A0 (https=) |
| NZ (1) | NZ512078A (https=) |
| PT (1) | PT1119630E (https=) |
| WO (1) | WO2000026385A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933366B2 (en) | 1996-12-27 | 2005-08-23 | Tripep Ab | Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
| US6660842B1 (en) | 1994-04-28 | 2003-12-09 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| US6802826B1 (en) | 1999-10-11 | 2004-10-12 | Felton International, Inc. | Universal anti-infectious protector for needleless injectors |
| US7887506B1 (en) | 1999-11-23 | 2011-02-15 | Pulse Needlefree Systems, Inc. | Safety mechanism to prevent accidental patient injection and methods of same |
| ATE320493T1 (de) * | 2000-06-22 | 2006-04-15 | Ucb Pharma Ltd | Modifizierung des hepatitis b kernantigens |
| CA2421877A1 (en) * | 2000-09-19 | 2002-03-28 | Tripep Ab | Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
| JP2004535799A (ja) * | 2001-05-18 | 2004-12-02 | パウダージェクト ワクチンズ，インコーポレーテッド | ワクチン組成物 |
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| EP1545593A1 (en) * | 2002-09-27 | 2005-06-29 | PowderJect Research Limited | Nucleic acid coated particles |
| US7335359B2 (en) | 2003-02-06 | 2008-02-26 | Tripep Ab | Glycosylated specificity exchangers |
| EP1594898A2 (en) | 2003-02-06 | 2005-11-16 | Tripep AB | Glycosylated specificity exchangers |
| JP2010505883A (ja) | 2006-10-12 | 2010-02-25 | ザ ユニバーシティー オブ クイーンズランド | 免疫応答を調節するための組成物および方法 |
| KR101413844B1 (ko) | 2008-12-09 | 2014-06-30 | 화이자 백신스 엘엘씨 | ＩｇＥ ＣＨ３ 펩티드 백신 |
| NZ598356A (en) | 2009-07-30 | 2014-06-27 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| PE20161551A1 (es) | 2009-09-03 | 2017-01-18 | Pfizer Vaccines Llc | Vacuna de pcsk9 |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| BR112013010926A2 (pt) | 2010-11-01 | 2016-08-23 | Univ Technology Sidney | agentes imunomoduladores e seus usos |
| CN103442732B (zh) | 2011-02-11 | 2017-04-12 | 宾夕法尼亚大学托管会 | 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗 |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
-
1999
- 1999-11-05 CA CA002349505A patent/CA2349505A1/en not_active Abandoned
- 1999-11-05 DE DE69929470T patent/DE69929470T2/de not_active Expired - Lifetime
- 1999-11-05 AT AT99963869T patent/ATE315658T1/de not_active IP Right Cessation
- 1999-11-05 WO PCT/US1999/026291 patent/WO2000026385A1/en not_active Ceased
- 1999-11-05 AU AU20222/00A patent/AU775939B2/en not_active Ceased
- 1999-11-05 JP JP2000579757A patent/JP2002528123A/ja active Pending
- 1999-11-05 NZ NZ512078A patent/NZ512078A/xx not_active IP Right Cessation
- 1999-11-05 ES ES99963869T patent/ES2257879T3/es not_active Expired - Lifetime
- 1999-11-05 PT PT99963869T patent/PT1119630E/pt unknown
- 1999-11-05 DK DK99963869T patent/DK1119630T3/da active
- 1999-11-05 EP EP99963869A patent/EP1119630B1/en not_active Expired - Lifetime
- 1999-11-05 IL IL14298099A patent/IL142980A0/xx unknown
-
2006
- 2006-04-07 CY CY20061100494T patent/CY1105600T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528123A5 (https=) | ||
| Ulrich et al. | Core particles of hepatitis B virus as carrier for foreign epitopes | |
| Celis et al. | Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen | |
| EP1685251B1 (en) | Nucleic acid constructs | |
| JP2004527213A5 (https=) | ||
| CA2413546A1 (en) | Modification of hepatitis b core antigen | |
| JP2001512748A5 (https=) | ||
| CA2305683A1 (en) | Immunogenic peptides from the hpv e7 protein | |
| US6492145B1 (en) | Vaccine against mycobacterial infections | |
| JP2002517249A5 (https=) | ||
| TW202245809A (zh) | 用於治療b型肝炎病毒感染之組合療法 | |
| Morgan et al. | Comparative immunogenicity studies on Epstein‐Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton‐top tamarins | |
| JP2010538629A (ja) | 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用 | |
| EP0913157B1 (en) | A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method | |
| JP2004536107A5 (https=) | ||
| JP2002515249A5 (https=) | ||
| CN118286410B (zh) | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 | |
| KR100686356B1 (ko) | 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제 | |
| Sjolander et al. | Bacterial Expression Systems Based on a Protein A and Protein G Designed for the Production of Immunogens: Applications to Plasmodium falciparum Malaria Antigens | |
| AU700104B2 (en) | Prolactin as a vaccine adjuvant | |
| CA2272051A1 (en) | Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation | |
| KR100905249B1 (ko) | Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션 | |
| JP2021040627A5 (https=) | ||
| JP2001517447A (ja) | Ｂ型肝炎ウイルスポリペプチド | |
| JP2021035361A5 (https=) |